Jesus Pacheco-Torres1, Marie-France Penet1,2, Yelena Mironchik1, Balaji Krishnamachary1, Zaver M Bhujwalla3,4,5. 1. Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Rm 208C Traylor Building, Baltimore, MD, 21205, USA. 2. Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. 3. Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Rm 208C Traylor Building, Baltimore, MD, 21205, USA. zbhujwa1@jhmi.edu. 4. Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. zbhujwa1@jhmi.edu. 5. Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. zbhujwa1@jhmi.edu.
Abstract
BACKGROUND: Harnessing the power of the immune system by using immune checkpoint inhibitors has resulted in some of the most exciting advances in cancer treatment. The full potential of this approach has, however, not been fully realized for treating many cancers such as pancreatic and breast cancer. Cancer metabolism influences many aspects of cancer progression including immune surveillance. An expanded understanding of how cancer metabolism can directly impact immune checkpoints may allow further optimization of immunotherapy. We therefore investigated, for the first time, the relationship between the overexpression of choline kinase-α (Chk-α), an enzyme observed in most cancers, and the expression of the immune checkpoint PD-L1. METHODS: We used small interfering RNA to downregulate Chk-α, PD-L1, or both in two triple-negative human breast cancer cell lines (MDA-MB-231 and SUM-149) and two human pancreatic ductal adenocarcinoma cell lines (Pa09C and Pa20C). The effects of the downregulation were studied at the genomic, proteomic, and metabolomic levels. The findings were compared with the results obtained by the analysis of public data from The Cancer Genome Atlas Program. RESULTS: We identified an inverse dependence between Chk-α and PD-L1 at the genomic, proteomic, and metabolomic levels. We also found that prostaglandin-endoperoxide synthase 2 (COX-2) and transforming growth factor beta (TGF-β) play an important role in this relationship. We independently confirmed this relationship in human cancers by analyzing data from The Cancer Genome Atlas Program. CONCLUSIONS: Our data identified previously unknown roles of PD-L1 in cancer cell metabolic reprogramming, and revealed the immunosuppressive increased PD-L1 effect of Chk-α downregulation. These data suggest that PD-L1 regulation of metabolism may be mediated through Chk-α, COX-2, and TGF-β. The observations provide new insights that can be applied to the rational design of combinatorial therapies targeting immune checkpoints and cancer metabolism.
BACKGROUND: Harnessing the power of the immune system by using immune checkpoint inhibitors has resulted in some of the most exciting advances in cancer treatment. The full potential of this approach has, however, not been fully realized for treating many cancers such as pancreatic and breast cancer. Cancer metabolism influences many aspects of cancer progression including immune surveillance. An expanded understanding of how cancer metabolism can directly impact immune checkpoints may allow further optimization of immunotherapy. We therefore investigated, for the first time, the relationship between the overexpression of choline kinase-α (Chk-α), an enzyme observed in most cancers, and the expression of the immune checkpoint PD-L1. METHODS: We used small interfering RNA to downregulate Chk-α, PD-L1, or both in two triple-negative humanbreast cancer cell lines (MDA-MB-231 and SUM-149) and two humanpancreatic ductal adenocarcinoma cell lines (Pa09C and Pa20C). The effects of the downregulation were studied at the genomic, proteomic, and metabolomic levels. The findings were compared with the results obtained by the analysis of public data from The Cancer Genome Atlas Program. RESULTS: We identified an inverse dependence between Chk-α and PD-L1 at the genomic, proteomic, and metabolomic levels. We also found that prostaglandin-endoperoxide synthase 2 (COX-2) and transforming growth factor beta (TGF-β) play an important role in this relationship. We independently confirmed this relationship in humancancers by analyzing data from The Cancer Genome Atlas Program. CONCLUSIONS: Our data identified previously unknown roles of PD-L1 in cancer cell metabolic reprogramming, and revealed the immunosuppressive increased PD-L1 effect of Chk-α downregulation. These data suggest that PD-L1 regulation of metabolism may be mediated through Chk-α, COX-2, and TGF-β. The observations provide new insights that can be applied to the rational design of combinatorial therapies targeting immune checkpoints and cancer metabolism.
Entities:
Keywords:
Breast cancer; COX-2; Choline kinase alpha; Immune checkpoints; PD-L1
Authors: Sonja Kleffel; Christian Posch; Steven R Barthel; Hansgeorg Mueller; Christoph Schlapbach; Emmanuella Guenova; Christopher P Elco; Nayoung Lee; Vikram R Juneja; Qian Zhan; Christine G Lian; Rahel Thomi; Wolfram Hoetzenecker; Antonio Cozzio; Reinhard Dummer; Martin C Mihm; Keith T Flaherty; Markus H Frank; George F Murphy; Arlene H Sharpe; Thomas S Kupper; Tobias Schatton Journal: Cell Date: 2015-09-10 Impact factor: 41.582
Authors: Rajani Ravi; Kimberly A Noonan; Vui Pham; Rishi Bedi; Alex Zhavoronkov; Ivan V Ozerov; Eugene Makarev; Artem V Artemov; Piotr T Wysocki; Ranee Mehra; Sridhar Nimmagadda; Luigi Marchionni; David Sidransky; Ivan M Borrello; Evgeny Izumchenko; Atul Bedi Journal: Nat Commun Date: 2018-02-21 Impact factor: 14.919
Authors: Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles Journal: Nature Date: 2018-02-14 Impact factor: 49.962
Authors: Hanne Lind; Sofia R Gameiro; Caroline Jochems; Renee N Donahue; Julius Strauss; James L Gulley; Claudia Palena; Jeffrey Schlom Journal: J Immunother Cancer Date: 2020-02 Impact factor: 13.751
Authors: Kimberly J Briggs; Peppi Koivunen; Shugeng Cao; Keriann M Backus; Benjamin A Olenchock; Hetalben Patel; Qing Zhang; Sabina Signoretti; Gary J Gerfen; Andrea L Richardson; Agnieszka K Witkiewicz; Benjamin F Cravatt; Jon Clardy; William G Kaelin Journal: Cell Date: 2016-06-30 Impact factor: 41.582
Authors: Geoffrey Alan Watson; Enrique Sanz-Garcia; Lillian L Siu; Eric Chen; Wen-Jiang Zhang; Zhihui Amy Liu; Sy Cindy Yang; Ben Wang; Shaofeng Liu; Shawn Kubli; Hal Berman; Thomas Pfister; Sofia Genta; Anna Spreafico; Aaron R Hansen; Philippe L Bedard; Stephanie Lheureux; Albiruni Abdul Razak; Dave Cescon; Marcus O Butler; Wei Xu; Tak W Mak Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Elizabeth R Stirling; Steven M Bronson; Jessica D Mackert; Katherine L Cook; Pierre L Triozzi; David R Soto-Pantoja Journal: Cells Date: 2022-01-05 Impact factor: 6.600